Cover - USD ($) $ / shares in Units, $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Mar. 27, 2026 |
|
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | This Amendment No. I on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of Aspire Biopharma Holdings, Inc. (the “Company”) for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 30, 2026 (the “Original Filing”). This Amendment is being filed: ● To file the Report of Independent Registered Public Accounting Firm of our predecessor auditor, Bush & Associates CPA LLC (the “Auditor Report”) related to the Company’s financial statements as of and for the year ended December 31, 2024, which was inadvertently omitted in the Original Filing. This Amendment is being filed solely to file the Auditor Report. No other changes were made to the Original Filing. Further, no attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the date of the Original Filing or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the registrant’s other filings with the Securities and Exchange Commission. This Amendment includes new certifications by the Company’s principal executive officer and principal financial officer as Exhibits 31.1, 31.2, 32.1 and 32.2, and the Auditor Consent as Exhibit 23.1. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2025 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity File Number | 001-41293 | ||
| Entity Registrant Name | Aspire Biopharma Holdings, Inc. | ||
| Entity Central Index Key | 0001847345 | ||
| Entity Tax Identification Number | 33-3467744 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | 23150 Fashion Dr. | ||
| Entity Address, Address Line Two | Suite 232 | ||
| Entity Address, City or Town | Estero | ||
| Entity Address, State or Province | FL | ||
| Entity Address, Postal Zip Code | 33928 | ||
| City Area Code | (908) | ||
| Local Phone Number | 987-3002 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Elected Not To Use the Extended Transition Period | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 17.4 | ||
| Entity Common Stock, Shares Outstanding | 5,024,124 | ||
| Documents Incorporated by Reference [Text Block] | None | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Listing, Par Value Per Share | $ 0.0001 | ||
| Auditor Firm ID | 76 | 6797 | |
| Auditor Opinion [Text Block] | We have audited the accompanying consolidated balance sheet of Aspire Biopharma Holdings, Inc. (the “Company”) as of December 31, 2025, and the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the year then ended, and the related notes to consolidated financial statements (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. | ||
| Auditor Name | Turner, Stone & Company L.L.P | Bush & Associates CPA LLC | |
| Auditor Location | Dallas, Texas | Las Vegas, Nevada | |
| Common Stock, par value $0.0001 per share [Member] | |||
| Title of 12(b) Security | Common Stock, par value $0.0001 per share | ||
| Trading Symbol | ASBP | ||
| Security Exchange Name | NASDAQ | ||
| Warrants, each exercisable for one share of common stock [Member] | |||
| Title of 12(b) Security | Warrants, each exercisable for one share of common stock | ||
| Trading Symbol | ASBPW | ||
| Security Exchange Name | NASDAQ | ||